Literature DB >> 21031547

Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis.

Cindy Ka Yee Cheung1, Chung Mau Lo, Kwan Man, George Ka Kit Lau.   

Abstract

Liver grafts from donors positive for antibody to hepatitis B core antigen (anti-HBc) may be used for transplantation in patients with hepatitis B virus (HBV)-related liver disease, and an occult HBV infection may develop from either source. Liver biopsy was performed for 31 patients who remained seronegative for hepatitis B surface antigen for a median of 44.5 months (range = 13.6-126.4 months) and received nucleoside analogue prophylaxis post-transplant. Nineteen of these recipients (61%) had received anti-HBc-positive grafts. Intrahepatic total HBV DNA and covalently closed circular DNA (cccDNA) levels were quantified, and the sequence was analyzed. Intrahepatic total HBV DNA and cccDNA were detectable in 26 (84%) and 16 (52%) of the 31 recipients, respectively, and they were more common when the donor was positive for anti-HBc (95% versus 67%, P = 0.038). The intrahepatic HBV DNA level correlated with the recipient pretransplant serum HBV DNA level (P = 0.06), and the intrahepatic HBV cccDNA level correlated with the donor intrahepatic HBV cccDNA level (P = 0.06). A phylogenetic analysis of the isolated HBV DNA sequence revealed HBV infections of both donor and recipient origins. In conclusion, an occult HBV infection after liver transplantation can originate from both the donor and recipient despite prolonged nucleoside analogue prophylaxis. The presence of intrahepatic HBV cccDNA is attributable more to the persistence of preexisting intrahepatic HBV cccDNA from a donor with previous exposure.
© 2010 AASLD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21031547     DOI: 10.1002/lt.22169

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  14 in total

1.  Prevention of post liver transplant HBV recurrence.

Authors:  Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2011-08-10       Impact factor: 6.047

Review 2.  Prophylactic managements of hepatitis B viral infection in liver transplantation.

Authors:  Takashi Onoe; Hiroyuki Tahara; Yuka Tanaka; Hideki Ohdan
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Molecular mechanisms underlying HBsAg negativity in occult HBV infection.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-24       Impact factor: 3.267

4.  Risk factors for de novo hepatitis B infection in pediatric living donor liver transplantation.

Authors:  Wei Rao; Man Xie; Tao Yang; Jian-Jun Zhang; Wei Gao; Yong-Lin Deng; Hong Zheng; Cheng Pan; Yi-He Liu; Zhong-Yang Shen
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Safety of Complete and Sustained Prophylaxis Withdrawal in Patients Liver-transplanted for Hepatitis B Virus-related Cirrhosis at Low Risk of Hepatitis B Virus Recurrence.

Authors:  I Lenci; G Tisone; D DiPaolo; Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 6.  Occult hepatitis B virus and hepatocellular carcinoma.

Authors:  Teresa Pollicino; Carlo Saitta
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 7.  Expanded criteria donors.

Authors:  Sandy Feng; Jennifer C Lai
Journal:  Clin Liver Dis       Date:  2014-08       Impact factor: 6.126

Review 8.  Occult HBV infection.

Authors:  Giovanni Raimondo; Gaia Caccamo; Roberto Filomia; Teresa Pollicino
Journal:  Semin Immunopathol       Date:  2012-07-26       Impact factor: 9.623

Review 9.  Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin.

Authors:  Bruno Roche; Anne Marie Roque-Afonso; Frederik Nevens; Didier Samuel
Journal:  Transplantation       Date:  2015-07       Impact factor: 4.939

Review 10.  The clinical significance of occult HBV infection.

Authors:  Giovanni Squadrito; Rosaria Spinella; Giovanni Raimondo
Journal:  Ann Gastroenterol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.